Oragenics, Inc. Announces the Completion of Enrollment for its ProBiora3® Clinical Trial at the University of Washington

Published: Sep 24, 2012

TAMPA, Fla.--(BUSINESS WIRE)--Florida-based biopharmaceutical company Oragenics, Inc. (OTCBB: ORNI) www.oragenics.com today announced the completion of the enrollment of their latest ProBiora3 human clinical study. The company is sponsoring the University of Washington School of Dentistry to conduct a 12 week, double-blind, placebo-controlled, randomized clinical study on ProBiora3. The study is assessing various microbiological, cosmetic and oral health indices on approximately 50 healthy subjects to further substantiate the benefits of ProBiora3. ProBiora3 is the result of over 25 years of research and is the active ingredient in Oragenics’ Evora brand of oral health products. ProBiora3 is a patented blend of three unique strains of beneficial bacteria that are naturally found in healthy mouths.

Back to news